High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.

When early toxicities (within 12 weeks of ICI therapy) were compared with delayed toxicities (>12 weeks of ICI therapy), T-cell richness was statistically higher in early toxicities, while there was a trend of higher T cell inverse Simpson and lower T-cell clonality although these differences did not reach statistical significance (p=0.06; figure 6 ).

also in 111,027 other papers